Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The opioid delta receptor (DOR), encoded by the OPRD1 gene, is a member of the opioid receptor family and a G protein-coupled receptor (GPCR). It is primarily activated by enkephalins and is involved in analgesia, mood regulation, and the reduction of gastrointestinal motility. DOR activation leads to inhibition of neuronal excitability along pain pathways and modulates both acute and chronic pain responses. It couples primarily to Gi/o proteins, leading to inhibition of adenylyl cyclase and modulates ion channels. Unlike other opioid receptors, DOR exhibits sustained antinociceptive effects via prolonged ERK activation from endosomal compartments. Delta-selective agonists are being investigated as novel analgesics with fewer side effects compared to mu-opioid drugs, and for their potential roles in treating mood disorders.
Activation of Gi/o proteins, inhibition of adenylyl cyclase, modulation of ion channels, ERK/PKC activation via endosomal signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Opioid Delta Receptor (DOR).